Utilize este identificador para referenciar este registo: https://hdl.handle.net/10216/128679
Registo completo
Campo DCValorIdioma
dc.creatorMarina Barroso Pereira Pinheiro
dc.date.accessioned2025-11-07T14:10:51Z-
dc.date.available2025-11-07T14:10:51Z-
dc.date.issued2020-05-11
dc.date.submitted2020-03-15
dc.identifier.othersigarra:414414
dc.identifier.urihttps://hdl.handle.net/10216/128679-
dc.descriptionAim: Design nanostructured lipid carriers (NLC) to facilitate drug delivery to tuberculosis-infected areas, exploiting macrophage mannose receptors and assess their uptake in a 3D human lung model. Materials & methods: NLCs and mannosylated-NLCs were synthetized and characterized. Their uptake and biocompatibility were tested in a 3D human lung model. Results: The formulations have appropriate size (170-202 nm) and morphology for lung deposition. Cell membrane integrity was maintained and no significant pro-inflammatory cytokine (IL-1β, IL-8 and TNF-α) secretion or morphological changes were observed 24 h post nanoparticles exposure. NLCs and mannosylated NLCs were distributed in the apical side of the lung tissue, both in macrophages and in epithelial cells. Conclusion: NLCs are biocompatible carriers and can be used for pulmonary drug delivery.
dc.description.abstractAim: Design nanostructured lipid carriers (NLC) to facilitate drug delivery to tuberculosis-infected areas, exploiting macrophage mannose receptors and assess their uptake in a 3D human lung model. Materials & methods: NLCs and mannosylated-NLCs were synthetized and characterized. Their uptake and biocompatibility were tested in a 3D human lung model. Results: The formulations have appropriate size (170-202 nm) and morphology for lung deposition. Cell membrane integrity was maintained and no significant pro-inflammatory cytokine (IL-1β, IL-8 and TNF-α) secretion or morphological changes were observed 24 h post nanoparticles exposure. NLCs and mannosylated NLCs were distributed in the apical side of the lung tissue, both in macrophages and in epithelial cells. Conclusion: NLCs are biocompatible carriers and can be used for pulmonary drug delivery.
dc.language.isopor
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-sa/4.0/
dc.subjectBiotecnologia médica
dc.subjectMedical biotechnology
dc.titleLipid nanoparticles biocompatibility and cellular uptake in a 3D human lung model
dc.typeDissertação
dc.contributor.uportoFaculdade de Medicina
dc.identifier.doi10.34626/345n-rk80
dc.identifier.tid202616444
dc.subject.fosCiências médicas e da saúde::Biotecnologia médica
dc.subject.fosMedical and Health sciences::Medical biotechnology
thesis.degree.disciplineMestrado Integrado em Medicina
thesis.degree.grantorFaculdade de Medicina
thesis.degree.grantorUniversidade do Porto
thesis.degree.level1
Aparece nas coleções:FMUP - Dissertação

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
414414.pdfLipid nanoparticles biocompatibility and cellular uptake in a 3D human lung model10.82 MBAdobe PDFThumbnail
Ver/Abrir


Este registo está protegido por Licença Creative Commons Creative Commons